Clinical Trial: Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT06942520) titled 'Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)' on Dec. 03, 2024.

Brief Summary: Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)

Study Start Date: March 18

Study Type: INTERVENTIONAL

Condition: Diabetic Macular Edema

Intervention: GENETIC: RGX-314 Dose 1

AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)

GENETIC: RGX-314 Dose 2

AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)

BIOLOGICAL: Aflibercept (2.0 mg)

Commercially available Active Comparator

Recruitment Stat...